Related Experiment Video
Updated: Jun 22, 2026

11:44
Stimulation of Cytoplasmic DNA Sensing Pathways In Vitro and In Vivo
Published on: September 18, 2014
CpG oligonucleotides activate the immune response in burned mice
Teru Yabuki1, Naoshi Takeyama, Masanobu Tsuda
1Department of Emergency and Critical Care Medicine, Kansai Medical University, Moriguchi, Osaka, Japan. yabuki@aichi-med-u.ac.jp
The Journal of Surgical Research
|June 23, 2009
Summary
Oligodeoxynucleotides containing CpG motifs partially reversed immunosuppression in burned mice. This treatment enhanced immune cell function, suggesting potential for treating post-burn immune dysfunction.
Area of Science:
- Immunology
- Burn Injury Research
- Therapeutic Development
Background:
- Burn injury leads to immunosuppression, increasing risks of sepsis and organ failure.
- Immune function changes post-burn injury require investigation for effective treatment strategies.
Purpose of the Study:
- To examine immune function alterations in mice following burn injury.
- To investigate the immunostimulatory effects of CpG-containing oligodeoxynucleotides (ODNs).
Main Methods:
- Burned mice underwent assessment of splenic macrophage immunological parameters.
- Splenic macrophages from burned mice were treated with ODNs in vitro to measure cytokine production and MHC class II expression.
- In vivo ODN administration to burned mice evaluated effects on splenic macrophage class II expression.
Main Results:
- Burn injury significantly reduced splenic macrophage class II antigen expression and cytokine production (IL-12, TNF-α, IL-6, IL-1).
- In vitro ODN treatment partially restored cytokine production by macrophages from burned mice.
- In vivo ODN administration enhanced class II antigen expression on splenic macrophages in burned mice.
Conclusions:
- CpG oligodeoxynucleotides partially reversed burn-induced reductions in splenic macrophage class II expression and cytokine synthesis.
- Immunostimulatory ODNs show promise as a potential therapeutic strategy for post-burn immunosuppression.

